NCT03070002
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells treatment 2 terminated NCT03359954
Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer No drug interventions treatment 2 active_not_recruiting NCT02648477
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer treatment 2 completed NCT03723928
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer No drug interventions health_services_research Not Available recruiting NCT03091842
Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer No drug interventions supportive_care Not Available withdrawn NCT01754519
Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery No drug interventions treatment 2 terminated NCT03128619
Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer treatment 1 terminated NCT03666819
Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy No drug interventions treatment 2 withdrawn NCT01319539
MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer No drug interventions treatment 2 terminated NCT01750073
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer treatment 2 active_not_recruiting NCT00785291
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer treatment 3 completed NCT01846091
Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer treatment 1 completed NCT03132467
Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer treatment 0 completed NCT03523195
Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors No drug interventions supportive_care Not Available completed NCT00390455
Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive treatment 3 completed NCT02152943
Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients treatment 1 completed NCT01275677
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer treatment 3 active_not_recruiting NCT02526498
Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery No drug interventions treatment 2 completed NCT03042897
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer No drug interventions supportive_care Not Available withdrawn NCT00338728
Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer treatment 2 completed NCT03691493
Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis treatment 2 completed NCT01281163
Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer treatment 1 terminated NCT00118157
Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen treatment 2 completed NCT01251874
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer treatment 1 completed NCT02398773
FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy diagnostic 2 active_not_recruiting NCT02219789
Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery treatment 1 completed NCT03377101
Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer treatment 2 withdrawn NCT02457910
Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer treatment 1 / 2 terminated